Skip to main content

SYSTEMATIC REVIEW article

Front. Genet.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1543261
This article is part of the Research Topic Post-Translational Modifications (PTMs) in Human Cancer: Pharmacological Insights and Therapeutic Opportunities View all 11 articles

Correlation and Clinical Significance of GSTP1 Hypermethylation in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Provisionally accepted
Lei He Lei He 1*Xinyao Huang Xinyao Huang 2*Rong Sun Rong Sun 3*Yan Zhang Yan Zhang 3*Yan Wang Yan Wang 3*
  • 1 Eastern Theater Command General Hospital, Nanjing, China
  • 2 Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China
  • 3 Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal cancers globally, with poor prognosis due to late-stage diagnosis and limited early detection methods.GSTP1 gene hypermethylation has been implicated in various cancers, including HCC, as a potential biomarker for diagnosis, prognosis, and therapeutic strategies. This systematic review and meta-analysis aimed to assess the association between GSTP1 hypermethylation and HCC, and its clinical significance.A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library to identify studies examining GSTP1 hypermethylation in HCC. Studies included in the meta-analysis were observational (case-control, cohort) or experimental studies (clinical trials) that reported on the correlation between GSTP1 hypermethylation and clinical outcomes in HCC patients.Pooled odds ratios (ORs) and weighted mean differences (WMDs) were calculated using random or fixed-effects models based on heterogeneity.A total of 10 case-control studies were included, comprising 1,133 participants. The analysis revealed a significant association between GSTP1 hypermethylation and the presence of HCC (OR = 6.64, 95% CI: 2.17-20.38). GSTP1 hypermethylation was more frequently observed in liver cancer tissue compared to liver tissue from patients with other diseases (P < 0.00001). Additionally, a significant correlation between GSTP1 hypermethylation and poor clinical outcomes, such as advanced tumor stage, recurrence, and reduced overall survival, was observed (OR = 2.56, 95% CI: 1.80-3.64).Subgroup analyses based on study design, sample type, and detection method showed no significant heterogeneity in most comparisons.GSTP1 hypermethylation is significantly associated with the presence of HCC and poorer clinical outcomes, making it a promising biomarker for early diagnosis and prognosis. These findings highlight the potential for GSTP1 methylation as a diagnostic and prognostic tool in HCC management. Further large-scale, multicenter studies are required to standardize detection methods and evaluate the therapeutic potential of epigenetic reactivation of GSTP1 in HCC patients.

    Keywords: Hepatocellular Carcinoma, GSTP1, hypermethylation, biomarker, diagnosis, prognosis, Meta-analysis

    Received: 11 Dec 2024; Accepted: 27 Jan 2025.

    Copyright: © 2025 He, Huang, Sun, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Lei He, Eastern Theater Command General Hospital, Nanjing, China
    Xinyao Huang, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China
    Rong Sun, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210093, Jiangsu Province, China
    Yan Zhang, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210093, Jiangsu Province, China
    Yan Wang, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210093, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.